MedPath

UK Government Invests £300M in Weight-Loss Drug Trials with Eli Lilly Partnership

• The UK government is investing nearly £300 million in trials for weight-loss jabs through a new partnership with Eli Lilly to address the obesity crisis. • A five-year trial in Manchester will assess the effectiveness of tirzepatide (Mounjaro), a rival to Ozempic, delivered in community settings. • The trial's results will inform NHS plans for a large-scale rollout of weight-loss drugs and explore digital tools to encourage healthy habits.

The UK government is set to invest nearly £300 million in trials for weight-loss jabs, partnering with Eli Lilly to combat the nation's growing obesity crisis. Eli Lilly will provide £279 million to fund research into effective weight management strategies.
The centerpiece of this collaboration is a five-year trial in Manchester, focusing on the weight-loss jab tirzepatide, marketed as Mounjaro. This drug is a direct competitor to Ozempic and will be administered in community settings to assess its real-world effectiveness.
The trial aims to provide data that will inform the National Health Service (NHS) on the potential for a large-scale rollout of weight-loss drugs. Researchers will also investigate the utility of digital tools, such as mobile apps, in promoting healthier lifestyles and sustained weight loss.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

UK Explores Weight Loss Drugs to Combat Unemployment in New Trial

The UK is initiating a trial in Greater Manchester to assess if Eli Lilly's weight loss drugs can reduce unemployment, addressing economic inactivity linked to long-term illness.
The study will involve 3,000 participants and aims to observe the long-term effects of drugs like Mounjaro and Zepbound on weight loss and employment status.

Weight-Loss Injections: The Science, Side Effects, and Pharmaceutical Race

Weight-loss injections like Wegovy and Mounjaro mimic hormones to control blood sugar and induce fullness, aiding in weight reduction.
Mounjaro, a dual-agonist targeting GLP-1 and GIP receptors, has demonstrated an average weight loss of 20% over two years, compared to 15% with Wegovy.

Eli Lilly's Mounjaro Set to Launch in Hong Kong, First of Its Kind in Greater China Region

Eli Lilly's Mounjaro (tirzepatide) is set to launch in Hong Kong by the end of the year, approved for both long-term weight management and type 2 diabetes treatment.
The Hong Kong launch of Mounjaro may attract customers from mainland China, where counterfeit versions of weight-loss injections are reportedly prevalent.

Eli Lilly's Tirzepatide Approved in Hong Kong for Weight Loss and Type 2 Diabetes

Eli Lilly has received approval in Hong Kong to sell its tirzepatide injections, branded as Mounjaro, for both long-term weight management and type 2 diabetes.
The drug will be available in a Kwikpen device, with sales expected to begin as early as the end of this year, intensifying competition in the Asian market.

Eli Lilly's Tirzepatide Approved in Hong Kong for Weight Loss and Type 2 Diabetes

Eli Lilly has received approval in Hong Kong to sell its tirzepatide injections, branded as Mounjaro, for weight management and type 2 diabetes.
The drug will be available in a Kwikpen device, offering a convenient delivery method for patients in Hong Kong.

Eli Lilly's Tirzepatide Approved in Hong Kong for Weight Management and Type 2 Diabetes

Eli Lilly has received approval in Hong Kong to sell its tirzepatide injections, branded as Mounjaro, for long-term weight management and type 2 diabetes.
The drug will be available in a Kwikpen device, with sales expected to begin as early as the end of this year, expanding access to this treatment option.

Eli Lilly's Tirzepatide (Mounjaro) Approved in Hong Kong for Weight Management and Type 2 Diabetes

Eli Lilly has received approval to launch its tirzepatide injections (Mounjaro) in Hong Kong for long-term weight management and type 2 diabetes.
The drug will be available in a Kwikpen device, offering a convenient administration method for patients in Hong Kong.

UK to Trial Eli Lilly's Mounjaro for Obesity to Boost Employment

The UK will conduct a major real-world study on Eli Lilly's tirzepatide (Mounjaro) to assess its effectiveness in helping obese individuals return to work.
The University of Manchester will coordinate the study, involving up to 3,000 participants, to evaluate the drug's impact on health-related quality of life and employment status.

Eli Lilly's Tirzepatide to Be Evaluated in Real-World Weight Loss Trial Targeting Employment Outcomes in Greater Manchester

A five-year clinical trial will assess tirzepatide's effectiveness on weight loss and preventing obesity-related complications in Greater Manchester.
The study will measure the drug's impact on employment status and sick days taken by participants.

NHS England Proposes Phased Rollout of Tirzepatide for Obesity Treatment

NHS England proposes a phased launch of tirzepatide (Mounjaro) to treat obesity, prioritizing patients likely to achieve the greatest clinical benefit from weight loss.
The rollout plan includes community-based services and digital technologies to deliver the injection to nearly 250,000 people in the first three years.

Reference News

[1]
Government to spend £300m on weight-loss drug trials - The Times
thetimes.com · Oct 15, 2024

£300 million invested in weight-loss jab trials by UK government and Eli Lilly. Five-year trial in Manchester to test Mo...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy